You are here

P&T® Journal contents for August 2007


In a study that examined whether PPIs were associated with the development of CDAD in hospitalized patients, the authors found that PPIs did not raise the incidence of this disease, which is caused by a prevalent bacterial infection.
Keithen Branch, PharmD, Vince Yahl, PharmD, BCPS, Karen Kier, PhD, MSc, BSPharm, Nancy Mertz, BBA, and Suzanne Marques, PharmD, BCPS
Meeting Highlights
Sessions from three meetings included discussions of arformoterol and indacatero­l for chronic obstructive pulmonary disease, pegylated interferon with or without ribavirin and its role in hepatitis C virus infection, ambrisentan for pulmonary­ arterial hypertension, and olmesartan/amlodipine combinations for hypertension.
Reuben B. David
Cover Story
The author presents a detailed account of the causes, diagnosis, prognosis, and therapies for colorectal cancer, including some promising biologic agents under development.
Marvin M. Goldenberg, PhD, RPh, MS
Book Review
Author: Robert I. Field, JD, MPH, PhD
Reviewed by Sara Thier, MPH


David Nash, MD, MBA, describes the effectiveness of various interventions in the uphill battle to motivate patients to comply with prescribed medication regimens.
David Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, shows how easy it is to confuse methyl­prednisolone acetate (Depo-Medrol) with methylprednisolone sodium succinate (Solu-Medrol).
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses a new Medicaid rule that may result in lower reimbursements to pharmacies for popular generic drugs.
Stephen Barlas
P&T presents the latest studies and information about FDA approvals, drug indications, and industry updates.
Drug Forecast
Drs. Sherwood, Rey, and Conwell review ramelteon (Rozerem) for patients with insomnia.
Devon A. Sherwood, PharmD, Jose A. Rey, PharmD, BCPP, and Michelle R. Conwell, PharmD